New injection aims to tame heavy periods

NCT ID NCT07169214

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This early-stage trial tests an injectable drug called BT-114143 in 39 women with abnormal uterine bleeding. Participants receive different doses twice daily for three days to see if it safely reduces bleeding. The study also checks for side effects and changes in blood clotting.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
BT-114143 injection
What this could lead to
If it works, this could provide a new treatment option to reduce heavy menstrual bleeding.
What could go wrong
This is an early Phase 1 trial with only 39 participants, so safety and effectiveness are not yet proven. The drug may not work or could cause side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ABNORMAL UTERINE BLEEDING are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Metrorrhagia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Peking Union Medical College Hospital

    RECRUITING

    Beijing, Beijing Municipality, 100730, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.